Satellos Bioscience Inc. (formerly iCo Therapeutics Inc.) is pleased to announce the completion, following the receipt of the final order of the Supreme Court of British Columbia on August 5, 2021, and subject to the final approval of the TSX Venture Exchange, of the previously announced reverse takeover transaction which was completed by way of plan of arrangement under Section 192 the Canada Business Corporations Act involving Satellos Bioscience Inc. and iCo Therapeutics Inc.